Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia

Leukemia

Volumn 19, Issue 6, 2005, Pages 971-977

  Yoshimi, A ^a   Bader, P ^b   Matthes Martin, S ^c   Stary J ^d   Sedlacek, P ^d   Duffner, U ^a   Klingebiel, T ^e   Dilloo, D ^f   Holter, W ^g   Zintl, F ^h   Kremens, B ⁱ   Sykora, K W ^j   Urban, C ^k   Hasle, H ^l   Korthof, E ^m   Revesz T ⁿ   Fischer, A ^a   Nollke P ^a   Locatelli, F ^o   Niemeyer, C M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e GOETHE UNIVERSITY   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k UNIVERSITY OF GRAZ   (Austria)

^l AARHUS UNIVERSITY   (Denmark)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^o FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation; Donor leukocyte infusion; Graft versus host disease; Graft versus leukemia effect; Juvenile myelomonocytic leukemia; Mixed chimerism

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CHIMERA; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; KARYOTYPE; LEUKOCYTE TRANSFUSION; LIVING DONOR; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SCHOOL CHILD; SIBLING; T LYMPHOCYTE; ALLOTRANSPLANTATION; CHILD; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; INFANT; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; RECURRENT DISEASE; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOCYTE TRANSFUSION; MALE; RECURRENCE; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 20044393759     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403721     Document Type: Article

References (41)

1. Niemeyer CM, Aricò M, Basso G, Biondi A, Cantù-Rajnoldi A, Creutzig U et al. Chronic myelomonocytic leukemia in childhood: a report of 110 cases. Blood 1997; 89: 3534-3543.
2. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277-282.
3. Hasle H, Niemeyer C. Myelodysplastic syndrome and juvenile myelomonocytic leukemia in children. In: Bennett JM (ed), The Myelodysplastic Syndromes. New York, Basek Marcel Dekker, Inc., 2002, pp 299-344.
4. Flotho C, Valcamonica S, Mach-Pascula S, Schmahl G, Corral L, Ritterbach J et al. Ras mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999; 13: 32-37.
5. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92: 267-272.
6. Tartaglia M, Niemeyer CM, Song X, Buechner J, Hählen K, Hasle H et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148-150.
7. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomoncytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410-419.
8. Manabe A, Okamura J, Yumura-Yagi K, Akiyama Y, Sako M, Uchiyama H et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002; 16: 645-649.
9. Locatelli F, Niemeyer C, Angelucci E, Bender-Götze C, Burdach S, Ebell W et al. Allogenic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15: 566-573.
10. Smith FO, King R, Nelson G, Wagner JE, Robertson KA, Sanders JE et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 2002; 116: 716-724.
11. Matthes-Martin S, Mann G, Peters C, Lion T, Fritsch G, Haas OA et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. Bone Marrow Transplant 2000; 26: 377-382.
12. Worth A, Rao K, Webb D, Chessells J, Passmore J, Veys P. Successful treatment of juvenile myelomonocytic leukemia relapsing post stem cell transplant using donor lymphocyte infusion. Blood 2003; 101: 1713-1714.
13. Pulsipher MA, Adams RH, Asch J, Petersen FB. Successful treatment of JMML relapsed after unrelated allogeneic transplant with cytoreduction followed by DLI and interferon-alpha: evidence for a graft-versus-leukemia effect in non-monosomy-7 JMML. Bone Marrow Transplant 2004; 33: 113-115.
14. Neudorf S, Nourani A, Kempert P, Shen V, Sender L, Kirov I. Chemotherapy and donor leukocyte infusions for relapsed juvenile myelomonocytic leukemia (JMML). Bone Marrow Transplant 2004; 33: 1069.
15. Bader P, Holle W, Klingebiel T, Handgretinger R, Niethammer D, Beck J. Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res 1996; 16: 1759-1763.
16. Lion T, Muller-Berat N. Chimerism testing after allogeneic stem cell transplantation: importance of timing and optimal technique for chimerism testing in different clinical-biological situations. Leukemia 1999; 13: 2059.
17. Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055-1060.
18. Allen RC, Graves G, Budowle B. Polymerase chain-reaction amplification products separated on rehydratable polyacrylamide gels and stained with silver. Biotechniques 1989; 7: 736-744.
19. Formankova R, Honzatkova L, Moravcova J, Sieglova Z, Dvorakova R, Nadvornikova S et al. Prediction and reversion of posttransplant relapse in patients with chronic myeloid leukemia using mixed chimerism and residual disease detection and adoptive immunotherapy. Leukemia Res 2000; 24: 339-347.
20. de Weger RA, Tilanus MGJ, Scheidel KC, van den Tweel JG, Verdonck LF. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Haematol 2000; 110: 647-653.
21. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
22. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
23. Fisher RA. Statistical Methods and Scientific Inference. Edinburgh: Oliver and Boyd ed., 1956.
24. Mann HB, Whitney DR. On a test of whether one or two random variables ist stochastically larger than the other. Ann Math Stat 1947; 18: 50-60.
25. Rassam SM, Katz F, Chessells JM, Morgan G. Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect? Bone Marrow Transplant 1993; 11: 247-250.
26. Kressler EJ, Haas OA, Konig M, Mann G, Mayer H, Peters C et al. Extramedullary relapse despite graft-versus-leukemia effect after bone marrow transplantation in a girl with juvenile myelomonocytic leukemia. Leukemia Lymphoma 1999; 33: 597-600.
27. Orchard PJ, Miller JS, McGlennen R, Davies SM, Ramsay NK. Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Bone Marrow Transplant 1998; 22: 201-203.
28. MacMillan ML, Davies SM, Orchard PJ, Ramsay NK, Wagner JE. Haemopoietic cell transplantation in children with juvenile myelomonocytic leukaemia. Br J Haematol 1998; 103: 552-558.
29. Ohta H, Kawai M, Sawada A, Tokimasa S, Fujisaki H, Matsuda Y et al. Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha. Bone Marrow Transplant 2000; 26: 681-683.
30. Lutz P, Zix-Kieffer I, Souillet G, Bertrand Y, Dhooge Y, Rubie H et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC childrens leukemia cooperative group (CLCG). Bone Marrow Transplant 1996; 18: 1111-1116.
31. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003; 121: 758-767.
32. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
33. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
34. van Rhee F, Savage D, Blackwell J, Orchard K, Dazzi F, Lin F et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055-1061.
35. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
36. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
37. Nadal E, Fowler A, Kanfer E, Apperley J, Goldman J, Dazzi F. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Experimental Hematology 2004; 32: 218-223.
38. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
39. Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487-495.
40. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696-1705.
41. Bernard F, Thomas C, Emile JF, Hercus T, Cassinat B, Chomienne C et al. Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood 2002; 99: 2615-2616.